Baxter International Inc.  

(Public, NYSE:BAX)   Watch this stock  
Find more results for Sebastian Huma�
-0.19 (-0.28%)
Feb 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 68.53 - 69.15
52 week 65.94 - 77.31
Open 68.70
Vol / Avg. 2.37M/3.58M
Mkt cap 37.22B
P/E 19.31
Div/yield 0.52/3.03
EPS 3.56
Shares 541.98M
Beta 0.73
Inst. own 82%
May 18, 2015
Baxter International Inc 2015 Investor Conference Add to calendar
Apr 15, 2015
Q1 2015 Baxter International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 10, 2015
Baxter International Inc at Barclays Healthcare Conference - 10:45AM EDT - Add to calendar
Mar 2, 2015
Baxter International Inc at Cowen Health Care Conference - 3:30PM EST - Add to calendar
Jan 29, 2015
Q4 2014 Baxter International Inc Earnings Release
Jan 29, 2015
Q4 2014 Baxter International Inc Earnings Call - Webcast
Jan 12, 2015
Baxter International Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Baxter International Inc at JPMorgan Healthcare Conference
Dec 2, 2014
Baxter International Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 11.72% 11.67%
Operating margin 16.70% 15.82%
EBITD margin - 25.57%
Return on average assets - -
Return on average equity - -
Employees 61,000 -
CDP Score - 78 C


United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Baxter International Inc. (Baxter) is a global, diversified healthcare company. The Company through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operates in two segments: BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics.

Officers and directors

Robert L. Parkinson Jr. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Sebastian J. Bufalino Corporate Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Todd S. Young Corporate Vice President, Treasurer
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Phillip L. Batchelor Corporate Vice President - Quality and Regulatory Affairs
Age: 52
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 51
Bio & Compensation  - Reuters
John Orloff M.D. Vice President, Global Head of Research and Development for Baxter BioScience
Bio & Compensation  - Reuters
Peter S. Hellman Lead Independent Director
Age: 64
Bio & Compensation  - Reuters